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A B S T R A C T
Schizophrenia is a complex mental health disorder. Clinical reports suggest that many patients 
with schizophrenia are less sensitive to pain than other individuals. Animal models do not 
interpret schizophrenia completely, but they can model a number of symptoms of the disease, 
including decreased pain sensitivities and increased pain thresholds of various modalities. Opioid 
receptors and endogenous opioid peptides have a substantial role in analgesia. In this 
biochemical study we investigated changes in the signaling properties of the mu-opioid (MOP) 
receptor in different brain regions, which are involved in the pain transmission, i.e. thalamus, 
olfactory bulb, prefrontal cortex and hippocampus. Our goal was to compare the transmembrane 
signaling mediated by MOP receptors in control rats and in a recently developed rat model of 
schizophrenia. Regulatory G-protein activation via MOP receptors were measured in [35S]GTPyS 
binding assays in the presence of a highly selective MOP receptor peptide agonist, DAMGO. It 
was found that the MOP receptor mediated activation of G-proteins was substantially lower in 
membranes prepared from the ‘schizophrenic’ model rats than in control animals. The potency of 
DAMGO to activate MOP receptor was also decreased in all brain regions studied. Taken 
together in our rat model of schizophrenia, MOP receptor mediated G-proteins have a reduced 
stimulatory activity compared to membrane preparations taken from control animals. The 
observed distinct changes of opioid receptor functions in different areas of the brain do not 
explain the augmented nociceptive threshold described in these animals.
Keywords: G-protein stimulation, [35S]GTPyS binding, brain membranes, opioid receptors, 
DAMGO, schizophrenia animal model
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1. INTRODUCTION
Schizophrenia is a chronic neuropsychiatrie disorder affecting approximately 1% of the 
population worldwide (for review see: Schultz et al. 2007; Sarkar et al. 2015). It affects equal 
numbers of men and women, but the onset is often later in women than in men. Schizophrenia is 
characterized primarily by positive and negative symptoms and cognitive disturbances. Positive 
symptoms include hallucinations, voices that converse with or about the patient, and delusions 
that are often paranoid. Negative symptoms include flattened affect, loss of a sense o f pleasure, 
loss of will or drive, and social withdrawal. Medical interventions can control especially the 
positive signs, but virtually all antipsychotics have neurologic or physical side effects.
Pain is a subjective phenomenon, not fully understood, which is manifested abnormally in most 
of the neurological disorders including schizophrenia (Antioch et al. 2015). Pain transmission is 
partially regulated by opioid receptors located in the central and peripheral nervous system. 
Heterogeneous opioid receptors (MOP, DOP and KOP receptors) are cell membrane integrated 
proteins belonging to the protein family of G-protein coupled receptors (GPCRs) (Al-Hasani and 
Bruchas, 2011; Feng et al. 2012; Benyhe et al. 2015; Thompson et al. 2015). GPCRs constitute 
the largest and physiologically very important membrane protein family that recognizes a variety 
of environmental stimuli, and are drug targets in the treatment of numerous diseases. Based on 
clinical studies, schizophrenic patients are often associated with abnormal pain sensitivity 
(Lévesque et al. 2012; Wojakiewicz et al. 2013). The causes and nature of insensitivity to pain in 
schizophrenia remain unknown. The role of endorphins and the association of cognitive 
dysfunction and negative symptoms have recently been postulated (Urban-Kowalczyk et al. 
2015).
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Developing valuable animal models for complex psychiatric disorders, including schizophrenia, 
is essential to increase our understanding of the neurobiological basis of the disease and for the 
development of effective drugs with improved therapeutic efficacy (Marcotte et al. 2001; Jones 
et al. 2011). Higher pain thresholds in thermal nociception but increased levels of mechanical 
allodynia have been observed by the use of two neurodevelopmental rat models of schizophrenia 
(Franék et al. 2010). All available animal models of this disorder fit into four different induction 
categories: developmental, drug-induced, lesion or genetic manipulation. Combination of the 
different methods in obtaining model animals for schizophrenia is more perspective to establish 
reliable animal model of the disease. Recently a chronic animal model starting from Wistar rat 
strain that shows some schizophrenia-related deficits by applying selective breeding after 
subchronic ketamine administration connected with postweaning social isolation (complex 
treatment) has been developed in our laboratory (Kékesi et al. 2015; Horváth et al. 2015). 
Distinct changes in central opioid receptor functions (Kékesi et al. 2011) and selective 
disturbance in pain sensation (Tuboly et al. 2009) have been described in naive animals after 
social isolation and ketamine treatment (Becker et al. 2003, 2006). The aim of the present study 
was to investigate and compare the MOP receptor mediated cellular signaling in four brain 
regions of ’the three hit schizophrenic’ model and control animals. Transmembrane signaling 
was in vitro triggered by the MOP receptor selective synthetic opioid peptide, DAMGO, and 
monitored by [35S]GTPyS binding experiments.
2. M A TE R IA LS  AND M ETH O D S
2.1 Animals
Two experimental groups of 12-12 rats were compared: naive socialized male Wistar rats 
without ketamine treatment (control group); and the 22nd generation of selectively bred male rats 
with social isolation and ketamine treatment (model group). All experiments were carried out
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with the approval of the Hungarian Ethical Committee for Animal Research (Reference number: 
XIV/03285/2011) in accordance with the European Communities Council Directives 
(86/609/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. 
32.x). The paradigm for selective breeding has previously been described (Petrovszki et al. 
2013). Briefly: Wistar rats, after weaning at 3 weeks of age, were tested with the tail-flick (TF) 
test (48 °C hot water) to assess pain sensitivity and then housed individually for 28 days. The 
animals were intraperitoneally (i.p.) treated with ketamine (Calypsol, Gedeon Richter Pic., 
Budapest, Hungary; 30 mg/kg, 4 mL/kg, daily, 5 times/week, 15 injections in total) from 5 to 7 
weeks of age. Then the animals were re housed (4-5/cage), and 1 week of recovery followed with 
no treatment. Starting at the age of 9 weeks, the pain sensitivity with TF test, the sensory gating 
with prepulse inhibition, and the cognitive functions and stereotypic behavior on hole-board test 
were assessed. Animals with the highest level of disturbances in these parameters were used for 
selective breeding throughout 22 generations (Petrovszki et al. 2013; Kékesi et al. 2015).
2.2 Chemicals
Tris-HCl, EGTA, NaCl, MgCl2 x 6H20 , GDP, the GTP analogue GTPyS, were purchased from 
Sigma-Aldrich (Budapest, Hungary). The highly selective MOP receptor agonist enkephalin 
analogue Tyr-D-Ala-Gly-NMePhe-Gly-ol (DAMGO) was obtained from Bachem Holding AG 
(Bubendorf, Switzerland). DAMGO was dissolved in water and was stored in 1 mM stock 
solution at -20  °C. The radiolabeled GTP analogue, [35S]GTPyS (specific activity: 3.7 x 1013 
Bq/mmol; 1000 Ci/mmol) was purchased from Hartmann Analytic (Braunschweig, Germany). 
The Ultima Gold™ MV harmless scintillation cocktail was purchased from PerkinElmer 
(Boston, USA).
2.3 Rat brain membrane homogenate preparation for G-protein activation assays
Control and model rats were decapitated and their brains were quickly removed, dissected on dry 
ice (prefrontal cortex, thalamus, olfactory bulb and hippocampus), frozen in liquid nitrogen and 
stored at -80  °C until further processions. The dissected parts of the brains were prepared for 
obtaining crude membrane fractions according to Benyhe et al, 1997 and used for the
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[35S]GTPyS binding experiments. Briefly, the carefully thawed and ice-cooled tissue samples 
were homogenized on ice in 50 mM Tris-HCl buffer (pH 7.4) using a Teflon-glass homogenizer. 
The homogenate was centrifuged at 40,000 x g for 20 min at 4 °C and the resulting pellet was 
resuspended in fresh buffer and incubated for 30 min at 37 °C. The centrifugation step was 
repeated with the same conditions, and the final pellet was resuspended in ten volume (10 ml 
buffer/g original tissue) ice-cold TEM buffer (50 mM Tris-HCl, 1 mM EGTA, 5 mM MgC^, pH 
7.4) to give an approximate protein concentration of 3-5 mg/ml. Protein concentrations were 
measured according to Bradford, 1976. Membrane samples were then aliquoted into Eppendorf 
tubes containing 40-60 pi membrane suspensions (enough for 24 reaction tubes in the binding 
assays) and stored at -80 °C for use.
2.4 Functional [35S]GTPyS binding assays
In [35S]GTPyS binding experiments we measured the GDP—>GTP exchange of the Gai/o 
proteins in the presence of a given ligand to determine the potency of the ligand and the maximal 
efficacy of the activated G-proteins. The nucleotide exchange is monitored by a radiolabeled, 
non-hydrolysable GTP analogue, [35S]GTPyS. The functional [35S]GTPyS binding experiments 
were performed as previously described (Traynor and Nahorski, 1995), with modifications. 
Briefly the membrane fractions were incubated in 24 polystyrene test tubes (Starstedt Co.) for 
one series at 30 °C for 60 min in Tris-EGTA buffer (pH 7.4) composed of 50 mM Tris-HCl, 1 
mM EGTA, 3 mM MgCh, 100 mM NaCl, containing 20 MBq/0.05 cm3 [35S]GTPyS (0.05 nM), 
around 10 pg/ml membrane protein and increasing concentrations (10"10 -  10'5 M) of DAMGO. 
The experiments were performed in the presence of excess GDP (30 pM) in a final volume of 1 
ml/reaction tube. Total binding was measured in the absence of test compounds, non-specific 
binding was determined in the presence of 10 pM unlabeled GTPyS and subtracted from total 
binding. The difference between total and non-specific binding values represents basal activity. 
The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester), 
and Whatman GF/B glass fiber filters were washed three times with 5 ml ice-cold 50 mM Tris- 
HCl (pH 7.4) buffer. The radioactivity of the dried filters was detected in Ultima Gold™ MV 
aqueous scintillation cocktail with Packard TriCarb 2300TR liquid scintillation counter. 
[35S]GTPyS binding experiments were performed in triplicates and repeated at least three times.
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2.5 Data analysis
Experimental data were presented as means ± S.E.M. Points were fitted with the professional 
curve fitting program, GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA), 
using non-linear regression analysis. In the [35S]GTPyS binding assays the ‘Sigmoid dose- 
response’ fitting was used to establish the maximal stimulation or efficacy (Emax) of the receptors 
G-protein and the ligand potency (EC50). Stimulation was given as percent of the specific 
[35S]GTPyS binding observed over the basal activity, which was settled as 100%. Unpaired t- 
tests with two-tailed P-value were performed to determine the significance level, using GraphPad 
Prism 5.0.
3. R ESU LTS
In agreement with our recent studies (Petrovszki et al. 2013; Kékesi et al. 2015; Horváth et al. 
2015), the selected model rats involved in the in vitro experiments showed decreased acute heat 
pain sensitivity indicated by longer tail-flick latency compared to the naive (control) rats. 
Accordingly, tissue samples from these animals were used to determine biochemical changes in 
the cellular signaling in both groups. The MOP receptor mediated G-protein activation was 
investigated by [35S]GTPyS binding stimulation assays as suggested by Traynor and Nahorski, 
1995. Cellular membranes were prepared from four brain regions o f control and ’schizophrenic’ 
model rats: prefrontal cortex, thalamus, olfactory bulb and hippocampus. MOP receptors were 
activated by the addition of DAMGO (Tyr-D-Ala-Gly-NMePhe-Gly-ol), a highly selective 
synthetic enkephalin derivative, first described and used by Handa et al, 1981. Beside morphine, 
the primary ligand for MOP receptor, the synthetic neuropeptide DAMGO also remained a gold 
standard in studying MOP receptor functions.
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Increasing concentrations of DAMGO produced dose-dependent stimulations of [35S]GTPyS 
binding in each brain region (Fig. 1). The highest activation of G-proteins was observed in 
membranes prepared from thalamus of control animals, while the lowest stimulation was found 
in hippocampal membrane preparations. In olfactory bulb membranes DAMGO mediated 
stimulation was also prominent and a moderate activation by the peptide was obtained in the 
prefrontal cortex. The presence of 10 pM naloxone, the general antagonist of multiple opioid 
receptors, was completely able to inhibit DAMGO mediated stimulations indicating the 
involvement of opioid receptors in the observed transmembrane signaling processes (data not 
shown).
MOP receptor mediated activation of G-proteins was consistently lower in membranes prepared 
from model/treated animals in each brain regions tested (Fig. 1, Table 1). The decrease in G- 
protein activation is characterized by lower maximal stimulation (Emax) values together with a 
rightward shift of the dose-response curves. Latter is associated with an obvious decrease in the 
ligand potency (-log EC50) values. Efficacy (maximal stimulation, Emax) changes were 
statistically significant in the case of thalamus (***, P=0.0007; two-tailed P value, t=9.434, 
df=4) and olfactory bulb (**, P=0.0036; two-tailed P value, t=6.107, df=4). F test to compare 
variances showed that variances were not significantly different. The observed decrease in Emax 
values in membranes prepared from prefrontal cortex and hippocampus was not significant. 
Decreases in potency values were seen in each brain regions, but the numeric change was 
statistically significant only in hippocampal membranes (**, P=0.0021; two-tailed P value, 
t=7.08, df=4), although the overall G-protein activation was the weakest in this preparation.
4. DISCUSSION
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Aberrations of pain experience occur frequently in psychiatric disorders and hence pathological 
alterations in the basic mechanisms underlying pain experience can be expected. Nevertheless, 
pain perception, as one of the most important basic mechanisms of pain experience, has rarely 
been assessed experimentally in psychiatric disorders. Review of clinical and experimental data 
indicates that in most situations behavioral pain reactivity and self-reported responses to pain are 
reduced in schizophrenia (de la Fuente-Sandoval et al. 2012; Lévesque et al. 2012; Wojakiewicz 
et al. 2013). However, there is little or no physiologic or biochemical evidence supporting pain 
insensitivity in schizophrenia. It can be suggested that the widely accepted notion of reduced 
pain sensitivity in schizophrenia is related more to a different mode of pain expression than to a 
real endogenous analgesia. Further studies are required and potential directions for future 
research are proposed to clarify this issue (Bonnot et al. 2009).
Endogenous analgesia, a likely cause of the decreased pain sensation is expected to be mediated 
at least partially by opioid receptors (Horváth and Kékesi, 2006; Costantino et al. 2012; Corder 
et al. 2013). The goal of the present study was therefore to investigate and compare the 
effectiveness of opioid peptide mediated signal transduction in different brain regions in normal 
control animals and in a recently developed animal model of schizophrenia (Petrovszki et al. 
2013; Horváth et al. 2015; Kékesi et al. 2015). Valuable animal models are important for the 
investigation of mechanisms and therapeutic approaches in various human neurological 
disorders. It was hypothesized that in the model animals an enhanced opioid receptor signaling 
occurs that can be a reason of the decreased pain sensitivity. Transmembrane signaling was 
studied in vitro by the use of [35S]GTPyS binding experiments in membranes prepared from four 
different regions of control and model rat brains. This is an accurate, relatively fast and trusty 
biochemical method to monitor signal transduction events (Traynor and Nahorski, 1994; Sim et 
al. 1995).
The brain regions used in our study were selected on the basis of their connection to either pain 
modulation or opioid receptor content. Thus prefrontal cortex has been proposed to control pain 
perception by modulating cortico-subcortical and cortico-cortical pathways (Lorenz et al. 2003).
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The thalamus is one of the important structures that receives projections from multiple ascending 
pain pathways and thalamic nuclei are involved in the sensory discriminative and affective 
motivational components of pain (Ab Aziz and Ahmad, 2006; You et al. 2013). Moreover, 
DAMGO was the most efficacious opioid agonist ligand in membranes prepared from rat 
thalamus in [35S]GTPyS binding experiments (Selley et al. 1997). The olfactory bulb is the first 
site for the processing of olfactory information in the brain and its deregulation is often 
associated with neurodegenerative disorders. Although this tissue is not directly connected to 
pain perception, a recent proteomic study about the molecular composition of the human 
olfactory bulb has shown the notable presence of proteins involved in opioid signaling 
(Femandez-Irigoyen et al. 2012). Hippocampus plays also an active role in suppressing pain 
especially during times of stress (Ford et al. 2011), and some abnormalities in hippocampal 
functioning with persistent pain has also been described (Mutso et al. 2012). The presence of 
MOP receptors in rat hippocampus has been confirmed by autoradiographic (Slamberova et al. 
2003) and immunohistochemical (Drake and Milner, 2002) studies.
Although an enhanced or at least not disturbed opioid mediated signaling was expected in the 
model animals, it was clearly found that G-protein activation via MOP receptors by the synthetic 
neuropeptide DAMGO was substantially decreased in each brain region studied. The impaired 
transmembrane signaling is characterized by lower efficacy values (Table 1) combined with a 
shift to the right of the DAMGO dose-response curves (Fig. 1). Some of the changes were indeed 
statistically significant. Similar results, i.e. decreased G-protein signaling by either ketamine 
treatment or social isolation in the full cortex of rat brain and spinal cord, were obtained at an 
earlier stage of the animal model used in this study (Kékesi et al. 2011). [35S]GTPyS binding was 
also determined in the prefrontal cortex and the hippocampus in an earlier model of 
schizophrenia (Becker et al. 2006). Analyzing [35S]GTPyS binding in the frontal cortex, a 
significant effect was found of housing conditions, suggesting increased efficacy in singly 
housed rats. Analysis amongst the four experimental groups failed to show significant 
differences. In the hippocampus, however, the experimental conditions had no effect and 
[35S]GTPyS binding was not changed as a result of ketamine pretreatment or housing conditions. 
The authors concluded that [35S]GTPyS binding was unaffected in the hippocampus, whereas it
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was increased in the frontal cortex of singly housed rats. Latter observation is in apparent 
conflict with our results found in the prefrontal cortex, which might be explained by the 
differences in the models and experimental arrangements used. Moreover, the increased G- 
protein stimulation in their saline injected single animals was decreased upon ketamine treatment 
indicating an impairment in G-protein signaling, which agrees with our observations. In further 
schizophrenia animal models based on phencyclidine (PCP) treatments a significant reduction in 
[35S]GTPyS binding connected with an increase in the levels of the endocannabinoid 2- 
arachidonoylglycerol (2-AG) in the prefrontal cortex was reported (Vigano et al. 2009). In the 
nucleus accumbens and ventral tegmental area the increased endocannabinoid levels were 
accompanied by unaltered CP55,940-stimulated [35S]GTPyS binding and CB1 cannabinoid 
receptor expression in PCP treated rats (Seillier et al. 2010). Taken together the decreased or 
unchanged G-protein activation profile is often present in various brain areas of different animal 
models of schizophrenia.
The observed inhibition of MOP receptor signaling in our model animals does not support the 
decreased pain sensitivity found in animal models of schizophrenia and in schizophrenic 
patients. Such a decrease in MOP receptor mediated transmembrane signaling would have led to 
hyperalgesia rather than an increased antinociception in the animals. Our results suggest that the 
decreased pain sensitivity observed in these animals could not be due to enhanced MOP receptor 
expression or signaling. Further studies are required to clarify the other potential mechanisms 
(e.g. changes in DOP or adrenergic, serotoninergic, cannabinoid receptor functions) of the 
hypoalgesia and the causes of decreased MOP receptor functions, e.g. the new substrain might 
have enhanced level of endogenous opioid ligands leading to MOP receptor internalization.
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Fig. 1
M OP receptor signaling mediated by D A M G O  in membranes prepared from four brain 
regions of control and model rats.
Percent increases (%) in the specifically bound radiolabeled nucleotide [35S]GTPyS are given 
over the basal (taken as 100%) activity as a function of increasing DAMGO concentrations (10'10 
-  10'5 M). Points represent mean values ±S.E.M. for three experiments performed in triplicate. 
„Basal” indicates constitutive G-protein activity level in the absence of any stimulating ligand.
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Table 1
G-protein activation by the M O P receptor agonist D A M G O  in different regional brain 
membrane preparations of control and model rats
Maximal stimulation (efficacy) D A M G O  Potency
Brain region in 
obtaining cell 
membranes
Emax ± S.E.M. (%) Log EC50 + S.E.M.
Control Model Control Model
Thalamus 223.3 ± 5.8 153.3 ±4.6*** -6.170 ±0.094 -6.459 ± 0.204ns
Olfactory bulb 192.4 ±2.3 169.7 ±2.9** -6.489 ± 0.059 -6.424 ± 0.089ns
Prefrontal cortex 164.3 ±3.9 152.1 ±  3.7ns -6.384 ±0.144 -6.052 ±0 .151NS
Hippocampus 127.5 ±0.8 123.3 ±4.4ns -7.491 ±0.101 -5.509 ±0.261**
Experimental data were processed by GrapPad Prism 5.0 using the sigmoid fit option of the 
dose-response curves. NS: not significant; **<0.01; ***, PO.OOl based on unpaired t-tests.
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